Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) has announced significant advancements in its barium and iodine contrast media projects, outlining a strategic roadmap to establish a vertically integrated supply chain for diagnostic imaging drugs. The company aims to address critical supply chain vulnerabilities in a market projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033, according to Research Contrast.
Voyageur is advancing two bankable feasibility studies (BFS) that underpin its vertical integration strategy: the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek (FC) barium contrast project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate, with recent testing confirming an average grade of 98.8% BaSO4, exceeding the pharmaceutical grade threshold of 97.5%. Voyageur has completed product development for five Health Canada approved barium products with Alberta Veterinary Laboratories, generating approximately C$32,000 in initial contrast product sales.
The company is pursuing FDA approval via the 505(b)(2) regulatory pathway, with the first drafts of all barium FDA submission documents completed and the process formally commenced in February 2026. The FDA review is anticipated to take 18 to 24 months, potentially enabling U.S. market entry by mid to late 2027. Voyageur also plans to advance a generic iodine FDA license in the second half of 2026.
For iodine, Voyageur is independently advancing a prefeasibility study integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform, targeting 35 million doses per year. The Bayer Iodine Project, supported by a US$2.35 million funding arrangement, focuses on completing a BFS. Subject to its success, Bayer may provide capital financing under an offtake-linked production financing arrangement, with Voyageur operating the project. All intellectual property will remain exclusively owned by Voyageur.
Voyageur is engaging a global engineering company to complete the two BFS, positioning the company to become the only vertically integrated manufacturer of barium and iodine contrast media globally. Management believes these efforts will provide affordable and secure supplies for healthcare authorities worldwide, reinforcing the company's value proposition: From Earth to Bottle.
